Investors looking for the next big move in biotech are watching the ALPS Medical Breakthroughs ETF (SBIO). The fund is doubling down on late-stage companies with major clinical milestones ahead and a real chance of being bought out. Recent price drops across the sector have not scared off the fund. Instead, some see this as a rare chance to get into a risky but opportunity-packed part of the market.
In September 2026, SBIO managed approximately $239.98 million in assets and held 105 stocks, with leading positions in CG Oncology, Travere Therapeutics, Oruka Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics, and Edgewise Therapeutics.
Volatility and high turnover come with the territory. For those willing to handle the swings, the fund’s method gives exposure to companies on the edge of big clinical events. These firms could deliver big gains or take hard hits, depending on how trials and deals play out.
Market data from Pluang as of September 23, 2026, shows just how fast things move in this space. Out of 100 tracked US health-sector stocks, 75 went up and 25 went down. DGX dropped to USD 234.76, down 4.13%, with a typical hold time of 55 days. INO rose 4.03% to USD 1.29, with all trades on the buy side. TXG climbed 4.01% to USD 82.27, but 96% of orders were sells, and the average hold time was 94 days.
According to Reuters, the biotech sector has seen a surge in M&A activity, with Telix Pharmaceuticals recently agreeing to acquire Germany's ITM Isotope Technologies Munich SE for up to $2.35 billion, including $1.65 billion upfront and up to $700 million tied to regulatory and commercial milestones for ITM-11.
Reuters reports that the biotech sector is still seeing sharp swings, driven by late-stage trial results and merger deals. Johnson & Johnson, for example, said its experimental use of Caplyta for bipolar mania hit its main goal in a late-stage study. This brings the drug closer to wider use. These are the kinds of clinical wins that SBIO looks for in its portfolio.
Reuters also notes that annualized returns for late-stage drug pipelines at big pharma companies are expected to be about 9% in 2026. That is down from an average of 11% between 2016 and 2024. This puts more pressure on the sector and has investors looking for assets with near-term catalysts, like those SBIO targets. The fund’s current profile, confirmed by independent aggregators, shows it is heavily invested in healthcare and biotech stocks, with very little cash on hand. This matches its focus on companies close to major clinical milestones.
The biotech field keeps changing. SBIO stays at the crossroads of clinical progress and deal-making, giving investors a front-row seat to the sector’s biggest developments.
